NuVasive Ready to Grow Beyond XLIF Roots

NuVasive reported 4Q21 orthopedic sales of $302.1 million, +3.5% vs. 4Q20. For the full year 2021, the company posted $1.1 billion in orthopedic sales, +8.4% vs. 2020. Compared to 2019, NuVasive slid -2.5%.

The company made headway in growing its presence in subsegments of spine where it had been traditionally underrepresented. NuVasive's...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us